Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Apr 4;29(16):2230–2239. doi: 10.1200/JCO.2010.33.7212

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 by American Society of Clinical Oncology

PMC Copyright notice

Fig 2. — (A) Relative mortality curves for patients with acute myelogenous leukemia (AML) receiving myeloablative allogeneic transplants surviving at least 2 years in remission post transplantation. (B) Relative mortality curves for patients with acute lymphoblastic leukemia (ALL) receiving myeloablative allogeneic transplants surviving at least 2 years in remission post transplantation. (C) Relative mortality curves for patients with myelodysplastic syndrome (MDS) receiving myeloablative allogeneic transplants surviving at least 2 years in remission post transplantation. (D) Relative mortality curves for patients with lymphoma receiving myeloablative allogeneic transplants surviving at least 2 years in remission post transplantation. (E) Relative mortality curves for patients with severe aplastic anemia (SAA) receiving myeloablative allogeneic transplants surviving at least 2 years in remission post transplantation.